Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN ), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.

Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.

Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI's team of data scientists and engineers.

Tevogen CEO, Dr. Ryan Saadi, commented, "Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI's vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare."

Strategic Partnerships:

Microsoft (Nasdaq: MSFT ): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.

Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen's AI models and enhance predictive accuracy.

Proprietary Tevogen.AI Technology:

PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.

The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio's pipeline. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.

AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.

AdapTcell is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.

Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.

Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Tevogen.AI.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MSFT
The Conversation (0)
Microsoft announces quarterly dividend

Microsoft announces quarterly dividend

Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.75 per share. The dividend is payable Sept. 12, 2024, to shareholders of record on Aug. 15, 2024. The ex-dividend date will be Aug. 15, 2024 .

Microsoft company logo. (PRNewsFoto/Microsoft Corp.) (PRNewsfoto/Microsoft Corp.)

Microsoft (Nasdaq "MSFT" @Microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/microsoft-announces-quarterly-dividend-302171319.html

SOURCE Microsoft Corp.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Nextech3D.ai Launches Next Era of GPT AI 3D Solutions Led by Former Microsoft Executive

Nextech3D.ai Launches Next Era of GPT AI 3D Solutions Led by Former Microsoft Executive

Transformative GPT AI Suite of a dozen 3D-AI Solutions To Lead Companies Growth

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:1SS), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls, Miele and others including major e-commerce platform integrations with Shopify, BigCommerce and WooCommerce is pleased to announce it is launching the next era of GPT AI 3D product solutions of proprietary Artificial Intelligence (AI) algorithms. The initiative will be led by former Microsoft Executive Hareesh Achi, who is Nextech3D.ai's current Head of Product Operations. The Company believes that the AI opportunity is in the early stages, and that the shift from 2D to 3D modeling for e-commerce is part of a major multi-decade transformation that is being led by AI. The Company is working on annual enterprise licensing deals for its suite of GPT AI solutions for 3D models and 3D maps

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Nextech3D.ai (CSE:NTAR, OTCQX:NEXCF, FSE:EP2)

Nextech3D.ai Partners With Pixelloid Studios to Hire Hundreds of 3D Artists in Its New Hyderabad, India Office in Anticipation of Rapid 3D Model Demand Growth in 2024

Nextech3D.AI (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is pleased to announce a partnership with Pixelloid Studios, a renowned creative studio specializing in 3D content creation and animation for Disney and others. Pixelloid has already graduated over 3000 students. Through this partnership, Nextech3D.ai is gaining access to a large talented and trained pool of students that have graduated from Pixelloid's advanced 3D training program. This partnership represents an essential step in Nextech3D.ai's ongoing efforts to address the increasing demand for 3D models from Amazon and others

Recognizing the surging demand for 3D models and the necessity to scale production, Nextech3D.ai has strategically chosen Hyderabad, India as the site for this expansion. Pixelloid Studios, who also has offices in Hyderabad will play a pivotal role in this initiative by training a team of skilled 3D model artists, who will integrate seamlessly into Nextech3D.ai's workforce in India. Nextech3D.ai sees these efforts as significantly enhancing its 3D model production capacity at lower costs, thus positioning the company for success in 2024.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Nextech3D.ai Expands Profit Margins and Slashes Overhead Costs as it Opens Office in Hyderabad India

Nextech3D.ai Expands Profit Margins and Slashes Overhead Costs as it Opens Office in Hyderabad India

Nextech3D.ai (the "Company") (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is pleased to announce the grand opening of its office space in Hyderabad, India. This expands Nextech3D.ai's profit margins and dramatically reduces overhead costs projected to save the Company as much as $4 million annually. The Company recently appointed Hareesh Achi as the new Head of Product Operations to lead this initiative. Hareesh has worked at industry titans MSFT & META for over a decade developing a deep-rooted understanding of managing big technology operations.Hyderabad has been crowned by investors as India's next startup powerhouse destination. "From 2014 to 2023, Hyderabad has emerged as a powerhouse in the Indian startup landscape. Its startup ecosystem now proudly boasts 4,369 tech startups."[1

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Nextech3D.ai (CSE:NTAR, OTCQX:NEXCF, FSE:EP2)

Nextech3D.ai Provides Business Updates on Its Business Units Powered by AI, 3D, AR and ML

Nextech3D.AI (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is pleased provide an update to the Company's investors on its four business units. As a diversified technology Company, each of its businesses ARitize3D, MapD, Toggle3D.ai, ARway.ai delivers a solution powered by ​proprietary AI, 3D, AR, ​and ML

The Company released its last shareholder update in June 2023, which outlined its Q1 highlights, 3D model updates including in partnership with Amazon, and its patents.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×